Understanding our story

One oral presentation and three posters support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces one oral presentation

Ohtuvayre TM (ensifentrine) now available; patient shipments started Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona

LONDON and RALEIGH, N.C., July 30, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the 44 th Annual Canaccord Growth Conference on Tuesday, August 13, 2024, at 1:30 p.m. EDT / 6:30 p.m.

LONDON and RALEIGH, N.C., July 25, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the second quarter ended June 30, 2024 on Thursday, August 8, 2024 and host an investment community conference call